Chembio Diagnostics (CEMI) Stock Price, News & Analysis

Company Overview

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Key Stats

• Today's Range: $0.45 to $0.46
• 50-Day Range: $0.33 to $0.46
• 52-Week Range: $0.19 to $1.24
• Volume: 351,642 shs
• Average Volume: 661,416 shs
• Market Capitalization: $16.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CEMI Stock Analysis - Frequently Asked Questions

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) posted its earnings results on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. The firm had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 113.57% and a negative net margin of 47.03%.

What other stocks do shareholders of Chembio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet (CLMT), Two Harbors Investments (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Viper Energy (VNOM) and Summit Midstream Partners (SMLP).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 7/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CEMI
• CIK: 1092662
• Web: www.chembio.com
• Phone: (631) 924-1135
• Fax: 631-924-2065
• Employees: 337
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.29 million
• Net Margins: -47.03%
• Pretax Margin: -46.96%
• Return on Equity: -113.57%
• Return on Assets: -38.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: $48.34 million
• Price / Sales: 0.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 36,726,000
• Free Float: 35,514,000
• Market Cap: $16.71 million
• Optionable: Not Optionable
• Beta: 1.85